Panel likely to study stent companies' demand on price cap

With the committee not finding any “therapeutic advantage” in these stents that favours price exemption, the issue is likely to be sent to an inter-ministerial group of experts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2o7EfUz
via IFTTT